Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells 25,000 Shares of Stock

Key Points

• Christobel Selecky, a director of ImmunityBio, disclosed selling a total of 75,000 shares this month—50,000 on Jan. 16 at $5.00 ($250,000) and 25,000 on Jan. 20 at $7.51 ($187,750)—in SEC filings.
• Regulatory discussions with the FDA provided a clear path to resubmit an sBLA for ANKTIVA, with the company planning to file additional information within 30 days, a catalyst that helped drive the recent share rally.
• The stock experienced heavy trading and momentum-driven volatility (moving up to about $6.92 during a multi‑session rally), while analyst opinions remain mixed—MarketBeat shows an average "Moderate Buy" rating with a $12 target amid both buy and sell calls.

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Christobel Selecky also recently made the following trade(s):

• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The shares were sold at an average price of $5.00, for a total value of $250,000.00.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX traded up $0.44 on Wednesday, hitting $6.92. 95,661,091 shares of the company were exchanged, compared to its average volume of 33,482,678. The firm has a market capitalization of $6.82 billion, a price-to-earnings ratio of -16.88 and a beta of 0.03. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $7.98. The company's 50 day moving average price is $2.54 and its two-hundred day moving average price is $2.52.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analyst estimates of $31.88 million. Research analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Institutional Trading of ImmunityBio

Several large investors have recently added to or reduced their stakes in the business. Slow Capital Inc. purchased a new position in ImmunityBio during the third quarter valued at approximately $25,000. Truist Financial Corp bought a new position in ImmunityBio during the third quarter valued at approximately $27,000. Swiss Life Asset Management Ltd bought a new stake in ImmunityBio in the third quarter worth $27,000. Diversify Advisory Services LLC purchased a new stake in shares of ImmunityBio during the 2nd quarter valued at about $27,000. Finally, Summit X LLC purchased a new position in shares of ImmunityBio in the 2nd quarter worth approximately $28,000. 8.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on IBRX. Weiss Ratings reiterated a "sell (e+)" rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an "overweight" rating in a report on Tuesday. D. Boral Capital reiterated a "buy" rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Finally, Jefferies Financial Group raised their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Friday, December 12th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ImmunityBio presently has an average rating of "Moderate Buy" and an average price target of $12.00.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.